These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35790913)

  • 1. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
    Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
    BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
    Rui YN; Xu Z; Chen Z; Zhang S
    Autophagy; 2015; 11(5):812-32. PubMed ID: 25984893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
    Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
    Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
    Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
    Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
    de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
    Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
    Vieri M; Preisinger C; Schemionek M; Salimi A; Patterson JB; Samali A; Brümmendorf TH; Appelmann I; Kharabi Masouleh B
    Carcinogenesis; 2021 Feb; 42(2):272-284. PubMed ID: 32915195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.
    Yamashita Y; Morita S; Hosoi H; Kobata H; Kishimoto S; Ishibashi T; Mishima H; Kinoshita A; Backes BJ; Yoshiura KI; Papa FR; Sonoki T; Tamura S
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
    Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
    Chen H; Yang H; Pan L; Wang W; Liu X; Ren X; Liu Y; Liu W; Zhang Y; Jiang L; Li K; Zhang B; Wang LX
    Biomed Pharmacother; 2016 Feb; 77():108-13. PubMed ID: 26796273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors.
    Xu G; Huang S; Peng J; Gao X; Li M; Yu S; Liu Z; Qie P; Wang Y; Yu S; Liu S; Wen H; Su L; Li P; Guang B; Dong R; Liu J; Yang T
    Br J Pharmacol; 2021 Dec; 178(23):4741-4757. PubMed ID: 34378191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
    Sun H; Lin DC; Guo X; Kharabi Masouleh B; Gery S; Cao Q; Alkan S; Ikezoe T; Akiba C; Paquette R; Chien W; Müller-Tidow C; Jing Y; Agelopoulos K; Müschen M; Koeffler HP
    Oncotarget; 2016 Apr; 7(14):18736-49. PubMed ID: 26934650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.
    Davenport EL; Moore HE; Dunlop AS; Sharp SY; Workman P; Morgan GJ; Davies FE
    Blood; 2007 Oct; 110(7):2641-9. PubMed ID: 17525289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.